SAN DIEGO — Use of metformin may offer some atherosclerosis protection for patients with type 1 diabetes but does not appear to improve glycemic control, new data suggest.

Findings from the double-blind, placebo-controlled Reducing with Metformin Vascular Adverse Lesions (REMOVAL) trial were

...
SAN DIEGO — Treatment options for sexual dysfunction in diabetic patients are surprisingly limited, and new therapeutic targets are needed for both sexes, according to new data presented here at the American Diabetes Association (ADA) 2017 Scientific Sessions.
 
To enable this, more information on
...
Those two words were woven through a Sunday morning address by Alvin C. Powers, MD, ADA President, Medicine & Science.
 
Today’s researchers and clinicians work in a 140-character, 24-hour news cycle, understanding that messaging is critical when trying to get the public’s attention, gain notice
...
SAN DIEGO — Meeting attendees are pushing back against the enforcement of severe restrictions on social media posts that discuss the American Diabetes Association (ADA) 2017 Scientific Sessionstaking place here this week.
 
Since the meeting began on Friday, June 9, many of the attendees' Twitter
...
SAN DIEGO — In a large Danish, longitudinal population-based study, boys who were overweight as children but who had returned to normal weight by age 18 did not have an increased risk of type 2 diabetes compared with those age 18 who had never been overweight in childhood.
 
"These findings suggest
...

SAN DIEGO — First data on use of a proprotein convertase subtilisin kexin 9 (PCSK9) inhibitor specifically in patients with diabetes failed to excite here at the American Diabetes Association (ADA) 2017 Scientific Sessions .

Alirocumab (Praluent, Sanofi/Regeneron Pharmaceuticals) met its primary efficacy end

...
Outstanding Educator in Diabetes Award recipient trumpets value of team-based care
Posted By: ADA Dailyon: June 11, 2017In: 2017, ADA Daily, All, Sunday
Print Email
Share0
Tweet
Share0
Share0
Share0
Davida F. Kruger, MSN, APRN-BC, BC-ADM
The Diabetes Control and Complications Trial (DCCT) did more than confirm
...
The Diabetes Prevention Program (DPP) started in 1996, but its benefits continue to improve the lives of those with diabetes and prediabetes, according to Brenda Montgomery, RN, MSHS, CDE, ADA President, Health Care & Education.
 
T2DM Can And Should Be Prevented 2017
 
During her presidential address
...
Fans of diabetes clinical trials rejoice: The American Diabetes Association (ADA) 2017 Scientific Sessions is your meeting.
 
Of course, the annual ADA conference always offers cutting-edge research on just about every aspect of diabetes for scientists, clinicians, other professionals, patients, and
...
NEW ORLEANS — New data from the EMPA-REG OUTCOME trial with the sodium-glucose cotransporter-2 (SGLT2) inhibitor empagliflozin (Jardiance, Boehringer Ingelheim) show that the drug significantly reduced the incidence of worsening nephropathy by 39% in the population of type 2 diabetes patients studied
...
NEW ORLEANS — Nearly closed-loop systems (also referred to as an "artificial pancreas") for improving glycemic control and minimizing hypoglycemia in type 1 diabetes are advancing rapidly, including iterations that deliver insulin alone, insulin with glucagon, or glucagon alone.
 
Findings for
...
NEW ORLEANS — Details of the Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results—A Long Term Evaluation (LEADER) trial of the glucose-lowering drug liraglutide (Victoza, Novo Nordisk), showing that it significantly reduced the rates of major adverse
...
SAN DIEGO — A talk on whether sulfonylureas still have a role in the contemporary treatment of type 2 diabetes
garnered much interest here at the American Diabetes Association (ADA) 2017 Scientific Sessions.
 
Speaking to a large audience in a packed room, Kamlesh Khunti, MD, from the University of
...

SAN DIEGO — New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), a 1 weekly given GLP-analog,  provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational

...

SAN DIEGO — New data from the Trial to Evaluate Cardiovascular and Other Long-term Outcomes With Semaglutide in Subjects With Type 2 Diabetes (SUSTAIN-6), a 1 weekly given GLP-analog,  provide a plausible explanation for the worsening retinopathy seen among patients taking the investigational

...
The risk of developing diabetic ketoacidosis (DKA) among type 2 diabetes patients initiating a sodium–glucose cotransporter 2 (SGLT2) inhibitor medication is about double that seen among patients starting a dipeptidyl peptidase-4 (DPP-4) inhibitor, but the overall risk is still low, new research
...
Type 2 Diabetes is a lifestyle disease that requires the person living with the disease to make many daily decisions about diet, activity level, and medications, as well as adequate support to manage the disease successfully.
 
Shared decision-making is a collaborative process that allows patients and
...
 
Researchers have tried many approaches to induce beta cells to proliferate and improve function, and most have failed. But several new approaches have emerged, including embryonic stem cells, genetic-based drug discovery, and novel signaling pathways.
 
Shuibing Chen, PhD
“Genome-wide association
...
 
During Saturday’s two-hour symposium Diabetes, Drugs and Heart Failure,, four experts will discuss several novel diabetes medications and their impact on heart failure.
 
Shannon M. Dunlay, MD, MS
Shannon M. Dunlay, MD, MS, opens the session with a review of the epidemiology of diabetes in heart
...
Although the latest high-density lipoprotein (HDL) clinical trials have not shown protection against cardiovascular disease, HDL research needs to continue, according to Alan T. Remaley, MD, PhD, one of the presenters for Saturday afternoon’s symposium The Atherogenic Dyslipidemia Complex—New
...
 
Continuous glucose monitoring (CGM) outcomes provide meaningful metrics for clinical trials and diabetes care, but the benefits can’t be demonstrated without a standard set of definitions, according to a panel of experts who spoke at a Friday symposium.
 
The researchers outlined three published and
...
For adults with hypertension treated with antihypertensive medication, reducing systolic blood pressure (SBP) levels to 120 to 124 mm Hg is associated with reduced risk of cardiovascular disease and all-cause mortality, according to a review published online May 31 in JAMA Cardiology.
 
Joshua D.
...
Investigational artificial-pancreas systems uniformly appeared to improve glycemic control in outpatients in a new systematic review and meta-analysis, despite the different technologies tested and varying clinical conditions in the included clinical trials.
 
The analysis, which included 24
...
Pressmeddelande från Sahlgrenska akademin vid Göteborgs universitet, tisdag den 6 juni 2017.
 
Publicering i Nature Communications i dag klockan 11:00. Artikeln nu synlig hos tidskriften efter viss fördröjning. 
 
Nyupptäckt sjukdomsmekanism för typ 2-diabetes
Nu presenteras en nyupptäckt mekanism bakom
...
The 77th Scientific Sessions will be held in USA, San Diego, CA from June 9-13, 2017.
 
More than 15,000 leading physicians, scientists and health care professionals from around the world convene each year at the American Diabetes Association’s Scientific Sessions to unveil cutting-edge research,
...